Henry Schein HSIC

Henry Schein, Inc. has reported notable earnings growth, with a strong third-quarter performance of $3.34 billion in net sales, exceeding expectations. The company raised its full-year EPS forecast and expanded U.S. distribution rights for Curodont, leading to a 15.4% rise in share prices over the past month. Despite challenges with organic revenue stagnation, its stock has surged nearly 24% over recent months, attributed to strategic moves like acquiring exclusive distribution for CytoChip’s FDA-cleared CitoCBC system. Henry Schein is implementing a roadmap to boost operating income by over $200 million, adapting to the evolving healthcare landscape while projecting continued growth in 2026.